Dutasteride for the treatment of benign prostatic hyperplasia. - Wikidata - awgldk - TriplyDB

Dutasteride for the treatment of benign prostatic hyperplasia.

Dutasteride for the treatment of benign prostatic hyperplasia.

http://www.wikidata.org/entity/Q34349726

about

Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers.Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.Effect of obesity and hyperglycemia on benign prostatic hyperplasia in elderly patients with newly diagnosed type 2 diabetes.Effects of dutasteride on serum free-testosterone and clinical significance of testosterone changes.Influence of dutasteride treatment on serum hormone levels and aging male symptoms in patients with benign prostatic enlargement.Relative Bioavailability of Fixed-Dose Combinations of Tamsulosin and Dutasteride: Results From 2 Randomized Trials in Healthy Male Volunteers.

P2860

Q38418380-588ADC03-1069-43D4-8D3C-11C99FE60093 Q38571198-4B0FF78D-4ADF-4D0B-9C6F-45FBF371E6CE Q38845916-895F77EE-AA10-4A47-968A-585DC5DCB51E Q41871759-DA939D3F-51A4-4F5F-804C-716C9176FF53 Q48853056-88A8D2C0-692D-4429-B5F5-8C37DA20BF1D Q49629325-F945BF06-8953-4DB5-B504-E9B5A873336B Q50505330-EC7F3130-B42A-4FB0-ACC0-8CB141B1E63F

P2860

Dutasteride for the treatment of benign prostatic hyperplasia.

http://www.wikidata.org/entity/Q34349726

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Dutasteride for the treatment of benign prostatic hyperplasia.

@ast

Dutasteride for the treatment of benign prostatic hyperplasia.

@en

Dutasteride for the treatment of benign prostatic hyperplasia.

@nl

type

label

Dutasteride for the treatment of benign prostatic hyperplasia.

@ast

Dutasteride for the treatment of benign prostatic hyperplasia.

@en

Dutasteride for the treatment of benign prostatic hyperplasia.

@nl

prefLabel

Dutasteride for the treatment of benign prostatic hyperplasia.

@ast

Dutasteride for the treatment of benign prostatic hyperplasia.

@en

Dutasteride for the treatment of benign prostatic hyperplasia.

@nl

P1433

Q34349726-55E6476E-0339-465F-9F0D-0B8FC711F5E5

P1476

Q34349726-C2125EA7-CE6F-4E35-9747-8C907AFAFC3A

P2093

Q34349726-908B1A3E-EE71-4075-8064-20E9C21BCDF0

Q34349726-B2572C95-3B27-4AF3-80B6-263080F8B711

P2860

Q34349726-053EBD91-A8D0-420D-B555-8BFB3E345B84

Q34349726-05D610D5-8FF8-4D22-9A47-0C9DACFC8453

Q34349726-12F5C2DD-FC63-4BA0-91CC-A39FC29199F4

Q34349726-13A0F668-774B-461A-9813-6EC984EF2B58

Q34349726-23545FFA-D19E-4D47-85E3-6491061E48A5

Q34349726-2A1F6B17-BD06-483E-A7EB-4CC172A25135

Q34349726-35DC42FB-04C0-4746-A9A0-67774BE151EE

Q34349726-37E8D594-840B-4B9F-AA20-DB3410EF787C

Q34349726-3BEE220E-3545-4260-936C-F10FD6B0F4F0

Q34349726-4097F61F-8BC3-4861-8595-DD7E6304D75C

P304

Q34349726-7361ECDB-05C6-447C-A59F-42165A2AE1AC

P31

Q34349726-59F65B3B-D80E-46FF-9151-71B00EB3DBB2

P356

Q34349726-B5470D27-40DF-4065-A2B7-FB2C1DA7F671

P407

Q34349726-439DCD4E-B5CA-4AB4-87F3-F820EF7055D4

P433

Q34349726-B87F81AE-AD1A-4BC6-9AD2-40C9CA17285F

P478

Q34349726-3519124B-29A2-4181-BC6C-140DA07516E4

P577

Q34349726-202D2333-5389-4985-BE9F-F4DF394F0B1E

P698

Q34349726-826B1FB8-64E1-44C7-998A-60525FDD4DBA

P356

14656566.2013.797965

P1433

Expert Opinion on Pharmacotherapy

P1476

Dutasteride for the treatment of benign prostatic hyperplasia.

@en

P2093

Anil Kapoor

http://www.w3.org/2001/XMLSchema#string

Christopher Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Relative potency of testosterone and dihydrotestosterone in preventing atrophy and apoptosis in the prostate of the castrated rat

Effect of dutasteride on the risk of prostate cancer.

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.

Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride.

Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor.

Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.

5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.

P304

1399-1408

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2013.797965

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23750593

http://www.w3.org/2001/XMLSchema#string